Peptides DB
Research-centric peptide and protocol reference hub
Study 50 of 52NAD+ (Nicotinamide Adenine Dinucleotide) literatureLancet (London, England)Top journal2026

Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial.

Not reported in abstract.

Read at Lancet (London, England)Add to compare

Where it sits

this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus
20
Preclinical
23
Observational
2
Open-label · this one
1
Randomised
6
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026

Abstract

The authors’ words, as Lancet (London, England) supplied them

<h4>Background</h4>Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) can compromise the administration and absorption of oral P2Y<sub>12</sub> inhibitors and carries high ischaemic and mortality risks. This trial assessed whether intravenous cangrelor was non-inferior to crushed oral ticagrelor for short-term clinical outcomes and whether it provided faster and more consistent platelet inhibition in patients with AMI-CS.<h4>Methods</h4>DAPT-SHOCK-AMI was a double-blind trial conducted at 29 hospitals across five European countries (Czech Republic, France, Germany, Poland, and Slovakia). Patients older than 18 years with AMI-CS were randomly assigned (1:1 ratio, stratified by centre, age, sex, presence or absence of ST-segment elevation, and mechanical ventilation) to cangrelor (30 μg/kg bolus followed by an infusion of 4 μg/kg per min for at least 2 h) or crushed ticagrelor (180 mg loading dose). The primary laboratory endpoint was a platelet reactivity index of less than 50% at the end of primary percutaneous coronary intervention. The primary clinical endpoint was death, myocardial infarction, or ischaemic stroke at 30 days. The primary clinical endpoint was analysed for non-inferiority with a prespecified margin of 1 percentage point among all randomly assigned patients who received study treatment. The study is registered with ClinicalTrials.gov (NCT03551964) and EudraCT (2018-002161-19); recruitment and 1-year follow-up are complete, and 5-year follow-up is ongoing.<h4>Findings</h4>Between Aug 1, 2018, and Jan 19, 2024, 605 patients (137 [23%] were female) were randomly assigned to cangrelor (n=298) or ticagrelor (n=307); no surviving patients were lost to the 1-year follow-up. The primary laboratory endpoint was analysed in 56 (19%) patients in the cangrelor group and 68 (22%) in the ticagrelor group, and was achieved in 56 (100%) of 56 patients receiving cangrelor and 15 (22%) of 68 receiving ticagrelor (p<0·0001). The 30-day primary clinical endpoint occurred in 112 (38%) of 298 patients receiving cangrelor and 126 (41%) of 307 receiving ticagrelor; non-inferiority was not demonstrated (difference -4 percentage points [90% CI -10 to 3]; P<sub>non-inferiority</sub>=0·13). Major bleeding at 30 days occurred in 19 (6%) of 298 patients receiving cangrelor and 16 (5%) of 307 receiving ticagrelor.<h4>Interpretation</h4>To our knowledge, this is the first randomised trial to compare P2Y<sub>12</sub> inhibitor strategies specifically in patients with AMI-CS. Cangrelor achieved effective platelet inhibition more frequently than crushed ticagrelor at the end of primary percutaneous coronary intervention. Non-inferiority of cangrelor versus crushed ticagrelor was not demonstrated for the primary 30-day clinical endpoint. These trial findings can inform future trials of P2Y<sub>12</sub> inhibition strategies in patients with AMI-CS.<h4>Funding</h4>Czech Republic Ministry of Health, Charles University (Czech Republic), and NextGenerationEU.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus

CA trapped catalytic product acts as molecular glue for innate immune signalosome assembly.Science (New York, N.Y.) · 2026 · Not reported in abstract.In vitroDPeripheral Blood NADP(H) Redox Metabolism in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-analysis Where Feasiblebiorxiv-preprint · 2026 · pooled effect for erythrocyte GR in AD was g=−1.05 (95% CI −2.73 to 0.63; I 2 =95.0%; five studies)reviewDThe bleeding edge of NAD in human ageing.Nature metabolism · 2026—DWhole-blood NAD levels track cardiovascular disease but not chronological age.Nature metabolism · 2026—CBioactive vitamin E-NAD<sup>+</sup> conjugate nanoparticles for osteoarthritis management via simultaneous suppression of inflammation and oxidative stress.Biomaterials · 2026 · Not reported in abstract.AnimalBNAD metabolism mediates a sex-specific protection against early life infectionsbiorxiv-preprint · 2026 · Higher birth NAD levels in females were associated with reduced infection burdens during the first 3 years of life.Human